28 C
Vientiane
Saturday, June 28, 2025
spot_img
Home Blog Page 140

LSBF Singapore Clinches Double Victory at the Employee Experience Awards 2025

Recognised for Best Organisational Change Leadership and Remote Work Strategy

SINGAPORE, May 26, 2025 /PRNewswire/ — The London School of Business and Finance (LSBF) Singapore Campus has emerged as a double winner at the highly acclaimed Employee Experience Awards 2025 held in Singapore. LSBF Singapore was honoured in two key categories: Best Organisational Change Leadership and Best Remote Work Strategy, a testament in fostering a supportive, adaptable, and high-performing work environment.

LSBF Singapore Clinches Double Victory at the Employee Experience Awards 2025
LSBF Singapore Clinches Double Victory at the Employee Experience Awards 2025

This remarkable dual win is a powerful endorsement of LSBF’s bold and people-first approach to navigating change and cultivating a thriving workforce. Amid a dynamic work landscape, LSBF has distinguished itself by reimagining organisational culture with clarity, compassion, and strategic foresight.

Securing the Best Organisational Change Leadership award, LSBF distinguished itself with a people-first approach to transformation—anchored in transparency, trust, and empowerment. Emerging as the winner among seven strong finalists, this recognition celebrates LSBF’s ability to navigate complex transitions with clarity and compassion, uniting its people around a shared purpose and resilient spirit.

Equally commendable is LSBF’s triumph in the Best Remote Work Strategy category, outshining global heavyweights such as Hewlett-Packard. Demonstrating bold leadership, LSBF has pioneered a vibrant, tech-driven, and inclusive remote work culture. Through digital collaboration tools and employee well-being initiatives, LSBF has redefined how teams stay engaged and inspired—regardless of geography.

“We are incredibly proud of this dual honour, which reflects our unwavering belief that our people are the heartbeat of LSBF,” said Rathakrishnan Govind, Global CEO, LSBF. “These awards affirm the culture of trust and inclusion, we’ve built together. We’re not just responding to change—we’re leading it.”

With this outstanding recognition, the education institution redefines what it means to be a great place to work, it remains committed to nurturing talent, driving purposeful growth, and shaping a workplace where everyone can shine.

About London School of Business & Finance (LSBF)

The London School of Business & Finance (LSBF), founded in 2003 and a member of the Global University System (GUS), serves over 25,000 students across more than 40 countries. With campuses in key cities including the UK, Singapore, and Malaysia, LSBF has expanded its international footprint, particularly in Asia. LSBF Singapore campus offers over 100 programmes in business, finance, law, hospitality, and technology, and collaborate with reputable universities to provide internationally recognised qualifications. LSBF holds EduTrust certification, partners with organizations like Grab, Deloitte and ISCA, and is an ACCA Approved Learning Partner. In recognition of its future-focused approach to education, LSBF was honoured with the Singapore Business Review’s International Business Award in Education for two consecutive years – 2024 and 2025. These accolades reaffirm LSBF’s commitment to delivering quality, industry-aligned education that empowers aspiring professionals globally.

Valtech Launches Free Startup Valuation Planning Tools in its Mobile App

KUALA LUMPUR, Malaysia and SINGAPORE, May 26, 2025 /PRNewswire/ — Valtech, an international innovator in valuation technology, has rolled out a major update to its mobile app, introducing an expanded suite of valuation tools tailored for startups. This significant release underscores Valtech’s commitment to supporting early-stage companies in navigating the fundraising process with clarity and confidence. The update includes two powerful additions: Startups Fundraising Valuation Planning and the Pre vs Post Money Valuation Calculator, designed to demystify the intricacies of valuation dynamics and equity structuring throughout successive funding rounds.

A Simple Way to Navigate Fundraising

At the heart of the update is the Startups Fundraising Valuation Planning module, an interactive and intuitive forecasting engine built specifically for early-stage businesses. This tool enables startup founders to simulate multiple rounds of funding, mapping out changes in ownership and company valuation from Angel and Seed rounds through to Series A, B, and C.

By entering key variables—such as the fundraising target for each round, the percentage of shares offered to new investors, the post-money valuation, and projected capital increases—founders receive an analytical breakdown of valuation growth and ownership dilution over time.

Pre vs Post Money Valuation Calculator

Complementing the planning module, the Pre vs Post Money Valuation Calculator provides a fast and simple way to assess investor equity stakes under various funding scenarios. Founders input their current pre-money valuation target, the percentage of shares they plan to issue to new investors, and their post-money valuation.

Based on these inputs, the calculator instantly derives the proportion of the company that will be owned by incoming investors on a fully diluted basis. The calculator is designed for founders and fund managers to do quick test when they are having face to face informal discussion on valuation. It helps avoid common misunderstandings about valuation terminology and ensures that cap table implications are fully grasped ahead of any deal.

A Connected Valuation Ecosystem for the Startup Journey

These new tools are part of Valtech’s broader initiative to provide a connected, user-centric platform for startups and valuation professionals. Within the app, users can:

  1. Explore Valtech’s global Service Catalog featuring detailed descriptions of valuation offerings across industries such as tech, healthcare, and real estate
  2. Access real-world Case Studies and testimonials to better understand valuation applications
  3. Connect via Live Chat with credentialed valuation experts (e.g. CFA, CPA, CVA, ABV by AICPA) for tailored guidance
  4. Receive assistance from Valtech’s AI Valerie, powered by a proprietary financial knowledge engine, for general enquiries on valuation

Valtech’s platform also opens doors for qualified professionals to join as expert partners, contributing their regional expertise while collaborating with a broader international network.

Redefining Accessibility in Valuation

This release marks a new chapter in Valtech’s mission to democratize professional-grade valuation tools. By combining an intuitive interface with versatile features, the app transforms an often opaque and technical process into a structured, strategic planning experience.

The Valtech App’s latest updates are available now on iOS and Android. Startups, investors, and experts worldwide can download the app to leverage Valtech’s end-to-end valuation ecosystem.

iOS: https://apps.apple.com/us/app/valtech-valuation-ai/id6743833382?l=en-GB

Android: https://play.google.com/store/apps/details?id=com.valtechvaluation.vip&hl=en

About Valtech Valuation

Valtech originated as a professional service from Asia, blending the distinct philosophies and strengths of Hong Kong SAR and Singapore to deliver international-caliber projects with dedication.

Valtech provides valuation services for cross-border transactions in almost every industry (including investment projects financed by the World Bank). Valtech’s qualified team comprises members with PhD, CPA, CFA, Chartered Valuation Surveyors of the Royal Institution of Chartered Surveyors, and valuers accredited with Business Valuation (ABV) by AICPA and CVA qualifications in Singapore.

For more information, visit: https://valtech-valuation.com

Media Contact:
Max Tsang / Marvin Wong / Jimmy Wong
T: +852 23889262
Email: admin@valtech-valuation.com

Singapore:
Ritika Gupta
+65 84949455
admin-sg@valtech-valuation.sg 

Mecpec Trading Received Shell’s Best Reseller in the East Award 2024


SINGAPORE – Media OutReach Newswire – 26 May 2025 – Mecpec Trading Co Pte Ltd, a distributor of petroleum-related products, was awarded the Best Reseller in the East by Shell in 2024. The award was based on Mecpec’s performance as a fuel reseller and its contribution to Shell’s distribution operations in Singapore.

Mecpec Trading Co Pte Ltd Recipient of Shell’s Best Reseller in the East Award
Mecpec Trading Co Pte Ltd Recipient of Shell’s Best Reseller in the East Award

Award Reflects Sales Growth and Market Contribution
Shell presented the Best Reseller in the East award to Mecpec in recognition of its recorded sales and delivery performance in 2023. Over the year, Mecpec achieved a total volume growth of 23%, including a 20% increase in Shell FuelSave Diesel sales. As Shell’s strategic distribution partner, Mecpec leveraged Shell’s Customer Value Propositions (CVPs) to broaden its market reach and effectively serve a diverse range of business sectors.

Commitment to Customer-Centric Solutions
As a fuel reseller, Mecpec supplies petroleum products to help businesses manage operational demands, delivering both cost efficiency and supply assurance. The company adopts a distribution approach that continuously adapts to evolving market conditions and the dynamic needs of its customers.

“We value our strong working relationship with Mecpec Trading for their consistent reliability and deep local market expertise,” said Glenn Chua, Shell Commercial Fuels Singapore Business Manager. “Their commitment to Shell’s standards of excellence has been instrumental in delivering value to our customers.

Mecpec applies its knowledge of petroleum products and market trends to deliver effective supply solutions to meet the diverse needs of companies across different scales and sectors. The company includes diesel refueling services as part of its supply package, along with fuel management solutions that help optimise fuel usage across sectors such as manufacturing, metal processing, and commercial vehicle operations.

Strengthening Distribution Infrastructure
The Best Reseller award acknowledges Mecpec’s ongoing role in supporting Singapore’s fuel distribution infrastructure. As a Shell partner, the company continues to invest in its operational capabilities by combining seasoned management expertise, specialised sales knowledge, and optimised delivery systems to maintain supply chain integrity and support business continuity for its diverse customer base.

For more information, visit www.mecpec.com.sg.
Hashtag: #MecpecTradingCoPteLtd #ShellPartnerAward #FuelReseller


The issuer is solely responsible for the content of this announcement.

About Mecpec Trading Co Pte Ltd

Founded in 1978 by Managing Director Philip Oh, Mecpec Trading Co Pte Ltd has grown from a one-man operation into an serving businesses across Singapore. Today, it operates a fleet of 25 trucks, supplying Diesel, Lubricants and Air1 AdBlue to organisations islandwide.

The company serves diverse industrial sectors, including construction, fleet and general manufacturing, through integrated refuelling services and petroleum product distribution. With 47 years of industry experience and strong relationships with major oil companies, Mecpec combines technical expertise with responsive service to meet evolving business requirements across Singapore’s industrial landscape.

World’s First — XellSmart’s Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial

SUZHOU, China, May 26, 2025 /PRNewswire/ — In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) for a Phase I clinical trial, to treat spinal cord injury (SCI)  a severe and currently untreatable disease of the central nervous system, affecting more than 15 million patients globally.

As the first regenerative clinical trial globally employing a subtype-specific neural progenitor cell therapeutic product to treat spinal cord injury, the study will be led by the Third Affiliated Hospital of Sun Yat-sen University, a nationally recognized leader in spinal cord injury treatment.

Spinal cord injury (SCI) is a globally prevalent neurological disorder. It represents a critical unmet clinical need, marked by a high rate of disability, irreversibility, early onset, and a significant burden on patients, families, and society. SCI primarily affects young and middle-aged adults, typically resulting from traffic accidents, sports injuries, or other traumas. As a condition that deeply affects a patient’s social function, it requires lifelong care and rehabilitation, leading to a significant economic burden and heavy societal costs. Beyond physical disability, SCI patients often face severe challenges in employment, social integration, and mental health. In high-income countries, lifetime healthcare and caregiving costs per patient may exceed USD 1 million, placing a heavy strain on both families and public health systems.

Worldwide, over 15 million people are estimated to suffer from spinal cord injury (SCI). This figure includes over 3 million patients in China and 300,000 patients in the US. Each year, China and the US report approximately 100,000 and 18,000 new cases of acute or subacute SCI — equivalent to nearly 10 and 2 new cases every hour, respectively.

SCI often leads to partial or complete paralysis, with the loss of motor and sensory function. Most patients experience permanent disability, severely compromising their quality of life. Due to the limited regenerative capacity of the central nervous system, nerve repair following SCI remains extremely challenging. Current treatments are largely limited to rehabilitation and supportive care, with no effective therapies available to promote neural regeneration during the injury phase.

Following over four years of rigorous development and preclinical studies, XellSmart has partnered with leading clinical experts in spinal cord injury to initiate the world’s first registrational clinical trial of an off-the-shelf, allogeneic, iPSC-derived, subtype-specific, regenerative neural cell therapy for spinal cord injury. This pioneering trial represents a landmark achievement in the global effort to develop regenerative therapies for spinal cord injury. Committed to advancing breakthrough treatments, XellSmart aims to redefine possibilities for SCI recovery — bringing a new hope to patients in China and around the world, and delivering tangible relief to families and communities affected by this devastating condition.

For funding and BD cooperation, contact: BD@xellsmart.com 

XellSmart has been dedicated to the development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. Up until now, XellSmart has secured formal approvals from both China’s NMPA and the U.S. FDA for seven registered and registrational clinical trials spanning China and the United States, for iPSC-derived cell therapies to treat CNS diseases  including Parkinson’s disease (Approved Phase I in both China and US), amyotrophic lateral sclerosis (ALS; Approved Phase I in both China and US; Global orphan drug designation by FDA), and spinal cord injury (SCI; Approved Phase I in both China and US), hence pioneering breakthrough advancements in tackling major and severe CNS diseases:

In 2023, China’s first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, received FDA approval and was granted global orphan drug designation (ODD).

In 2024, China’s first national-level registered clinical study of iPSC-derived cell therapy for neurological diseases was approved to treat Parkinson’s disease patients—including China’s first case. More than 12 months of follow-up demonstrated good safety and significant improvements in “off” time, MDS-UPDRS scores, and multiple non-motor symptoms.

In 2024, the world’s first national-level registered clinical study of iPSC-derived cells (XS228 injection) for amyotrophic lateral sclerosis (ALS) was approved. Multiple ALS patients including the world’s first case were treated safely, with preliminary data showing effective slowing of disease progression.

In 2025, China’s first allogeneic off-the-shelf iPSC-derived dopaminergic neural progenitor cell (XS411 injection) registrational Phase I clinical trial was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital, targeting Parkinson’s disease — the world’s second most common neurodegenerative disorder.

In 2025, China’s first randomized, double-blind controlled registrational Phase I/II clinical trial was launched, led by Huashan Hospital affiliated with Fudan University (also a National Neurological Disease Medical Center), targeting early-onset Parkinson’s disease (EOPD).

In 2025, the world’s first registrational Phase I/II clinical trial of an allogeneic off-the-shelf iPSC-derived subtype-specific neural progenitor cell therapy (XS228 injection) was launched by Peking University Third Hospital, targeting amyotrophic lateral sclerosis (ALS), one of the world’s four major incurable diseases.

In 2025, the world’s first registrational Phase I clinical trial of an allogeneic off-the-shelf iPSC-derived subtype-specific neural progenitor cell therapy was initiated by the Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI), a major neurological disease.

XellSmart has established a fully dedicated, internationally competitive “All-In” team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. XellSmart has independently built and operates a R&D center, a B+A-grade GMP manufacturing facility and a quality control center with a total area exceeding 5000m2.

Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple national, registered or registrational clinical studies and global clinical trials.

XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others.

For funding and BD cooperation, contact: BD@xellsmart.com 

French Cream: The Secret Ingredient to Perfect Desserts and Culinary Excellence

Renowned for its richness, purity, and versatility, French cream remains the preferred choice of chefs and culinary artisans worldwide.

SINGAPORE, May 26, 2025 /PRNewswire/ — From the lush pastures of Normandy to the culinary capital of Paris, French cream has long held a place at the heart of fine cuisine. Celebrated for its exceptional quality, smooth texture, and rich flavor, it reflects generations of savoir-faire, a blend of tradition, terroir, and expert craftsmanship.

Produced under strict quality standards and sourced from pasture-raised cows, French cream offers a naturally velvety consistency and a high butterfat content, lending depth and elegance to both sweet and savory creations. Whether whipped into airy peaks for pastries, folded into classic French sauces, or used in iconic dishes like crème brûlée, it delivers unmatched versatility and consistency.

“French cream is not just an ingredient—it’s an expression of craftsmanship and culinary heritage,” says Emilie Martin, Managing Director APAC, CNIEL. “Its unique qualities make it an essential element in kitchens around the world, from Michelin-starred restaurants to passionate home bakers.”

Celebrating Three Years of Culinary Collaboration in Singapore

Over the past three years, the French cream campaign run by CNIEL and co-funded by the European Union, has proudly partnered with some of Singapore’s most celebrated chefs to highlight its excellence and adaptability. Through culinary workshops, tasting sessions, and masterclasses, these chefs have demonstrated how French cream elevates both traditional French desserts and inventive Asian-inspired dishes.

As Chef Cheryl Koh of Les Amis shared, “I only work with French cream, for its flavor, texture, and color. I use liquid cream, fresh cream, and fleurette cream. It has a fresh and pleasant flavor, whips beautifully, and has a wonderful texture.”

French cream has long been the heart of dessert-making, blending flavor and texture to add elegance and richness to every bite. says Chef Alicia, Nesuto

Savoring Singapore: A Culinary Adventure

In 2025, Singapore continues to celebrate French cream through a series of dynamic, hands-on events bringing together professionals, aspiring chefs, and food lovers.

The 3rd Rising Pastry Award: A Celebration of Tomorrow’s Stars

On May 15th, 2025, At-Sunrice Global Chef Academy hosted the 3rd edition of the Rising Pastry Award, a prestigious competition designed to spotlight the region’s most promising young pastry chefs and home bakers. This year’s winner earned a once-in-a-lifetime opportunity to attend a five-day pastry course at the esteemed École Ducasse in France, alongside other ASEAN finalists.

A distinguished panel of judges—including Chef Alicia Wong (Nesuto), Chef Alice Hsiao (Tarte), Chef Kelly (The Prestine, Hyatt), Chef Cindy Khoo (Hyatt), and Chef Frank (At-Sunrice)—evaluated the finalists and awarded the grand prize to Stacy Kwek (@sk.staceyyy), whose inventive creation showcased the elegance and versatility of French cream.

“Competing in the Rising Pastry Chef competition was an incredible first experience that pushed me out of my comfort zone and helped me grow under pressure. I gained valuable insights, made new friends, and learned from other talented chefs. I’m truly grateful for the opportunity, the support, and the positive feedback that boosted my confidence”, the winner said.

Reflections from Past Winners

Last year’s winner, Casey, shared:

“The experience in France was unforgettable. Exploring pastry shops, tasting unique combinations of local fruits and French cream, and attending MOF-led classes at École Ducasse taught me invaluable techniques and deepened my pastry knowledge.”

The Year 1 winner, Kirsten, also reflected fondly on her journey:

“Joining this competition back in 2023 was unexpected. I was blessed to win and enjoy a memorable week at Ferrandi School in Paris. I appreciate it immensely. A big thank you to the team for organizing such a great event.”

What’s Next for French Cream in 2025

The campaign continues with a rich calendar of events:

  • Student Workshops: Future pastry talents will participate in hands-on workshops at ITE Culinary School and At-Sunrice Global Chef Academy with Chef Cheryl Koh from Les Amis, who will mentor aspiring young chefs in advanced pastry techniques using French cream.
  • Trade Demonstrations: Chef Alicia Wong (Nesuto) will headline an exclusive industry event, exploring French cream’s creative potential in modern desserts.
  • Media Gatherings: Influencers and journalists will be invited to an exclusive tasting experience, an intimate celebration of French elegance and culinary artistry.

The Recipe – Introducing the Exclusive Pandan Gateau Basque by Chef Alicia, Nesuto

In this exclusive creation to celebrate Singapore’s 60th anniversary, Chef Alicia pays tribute to heritage through innovation. Known for her refined technique and cultural sensitivity, she shares the inspiration behind her latest dessert, a Pandan Gâteau Basque: “In my kitchen, I’m drawn to infusion—a method that draws out delicate flavors and transforms them into new textures. For this recipe, I wanted to highlight pandan, a Southeast Asian staple often seen in heritage sweets. Inspired by familiar local treats like egg tarts and refined by French pastry techniques, I created a Pandan Gâteau Basque with a touch of rose—nostalgic yet intentional, honoring tradition through a contemporary lens.”

For the video recipe and expert tips directly from Chef Alicia, visit https://www.creamessential.com/sg and start creating your own exquisite Pandan Gateau Basque today.

Gateau Basque
Gateau Basque

Gateaux Basque Dough 

Ingredients: 

  • Whole eggs – 50g 
  • Egg yolks – 20g 
  • Icing sugar – 200g 
  • Salt – 1.5g 
  • Plain flour – 560g 
  • Chilled cubed butter – 280g 
  • Whipping cream – 80g 

Instructions: 

1. Chill Ingredients: 

  • Chill the butter, plain flour, and icing sugar in the fridge. 

2. Mix Wet Ingredients: 

  • In a bowl, whisk together the whole eggs, egg yolks, whipping cream, and salt. Set aside. 

3. Make Dough Base: 

  • In a food processor, combine the chilled butter, plain flour, and icing sugar. Pulse until the mixture resembles coarse crumbs. 

4. Combine Wet and Dry: 

  • Add the egg mixture to the dough base and mix in a stand mixer until combined. 

5. French “Frassage” Method: 

  • Turn the dough onto a work surface. Gently work it with your hands using the “frassage” method until smooth. 

6. Chill Dough: 

  • Wrap the dough in plastic wrap and refrigerate for 1–2 hours. 

7. Roll and Line Tart: 

  • After chilling, roll the dough to your desired thickness. Line the tart ring with the dough and refrigerate while preparing the custard. 

Gateaux Basque Custard 

Ingredients: 

  • Salt – 1.2g 
  • Milk – 400g 
  • Cream – 320g 
  • Sugar – 72g 
  • Cornstarch – 32g 
  • Plain flour – 28g 
  • Egg yolks – 48g 
  • Pandan leaves – 40g 

Instructions: 

1. Infuse Milk and Cream: 

  • Cut the pandan leaves and combine them with milk, cream, and salt. Vacuum pack the mixture and place it in a water bath at 60°C for 30 minutes. 

2. Blend and Strain: 

  • After 30 minutes, blend the mixture using a hand blender. Fine-strain it into a pot and add 50% of the sugar. 

3. Prepare Egg Mixture: 

  • In a bowl, whisk together the cornstarch, plain flour, egg yolks, and remaining 50% of the sugar. Set aside. 

4. Temper Eggs: 

  • Bring the infused milk mixture to a simmer. Gradually temper it into the egg mixture, then return to the pot. 

5. Cook Custard: 

  • Cook over medium heat, whisking constantly, until the custard thickens. 

6. Cool Custard: 

  • Pour the custard onto a tray and allow it to cool completely. 

Final Assembly 

1. Fill Tart Shell: 

  • Fill the chilled tart shell with the cooled custard, smoothing the top. 

2. Top with Dough: 

  • Roll out the remaining dough and place it on top of the custard. Seal the edges. 

3. Egg Wash and Design: 

  • Brush the top with egg wash and create a design using a fork or pick. 

4. Chill and Bake: 

  • Chill the assembled gateaux in the fridge for 2–3 hours. Preheat the oven to 170°C and bake until golden brown. 

To discover more recipes with French cream by renowned chefs accross Asia please go to the CREAM ESSENTIAL website https://www.creamessential.com/sg

#EuropeanCream #FrenchCream #HolidayDesserts #EnjoyItsFromEurope #FrenchCreamSg @creamessentials_sg

Industry Forums at 137th Canton Fair Spotlight Emerging Trends and Global Strategies

GUANGZHOU, China, May 26, 2025 /PRNewswire/ — The 137th China Import and Export Fair (Canton Fair) hosted a series of high-level industry forums, bringing together government officials, financial institutions, business leaders, and subject matter experts. These sessions explored evolving global trade dynamics and offered strategic guidance to Chinese enterprises pursuing international growth.


A standout session on April 17, titled “The New Ecosystem of AI + Consumer Electronics,” focused on how artificial intelligence is transforming the consumer electronics landscape. Discussions emphasized intelligence, personalization, and contextual innovation as key drivers of the sector’s next wave of growth. Leading voices from companies such as Lianlian Global and iFLYTEK shared insights on leveraging AI to create competitive advantages. The forum also marked the release of a white paper that offered practical strategies across six major product categories. Case studies demonstrated how China’s R&D-led and globally integrated production model reshaped global markets.

On April 23, another pivotal forum addressed brand globalization in the home and construction materials sector. Experts and company leaders shared approaches for strengthening reach in the international market. Professor Dai Yonghong of Shenzhen University emphasized the importance of combining AI with a deep understanding of Chinese market strengths to navigate global trade uncertainties. Shi Zhicheng from the China Quality Certification Center highlighted the need to embed carbon reduction strategies in line with China’s dual carbon goals. Customs expert Zu Xiaomin explained how the AEO (Authorized Economic Operator) system facilitates smoother international expansion for certified enterprises. A roundtable featuring executives from several furnishing companies illustrated a key shift in China’s manufacturing—moving from cost-driven competitiveness to a focus on quality and branding.

Additional forums throughout the 137th Canton Fair explored global opportunities across different sectors. The April 25 forum titled “The Rising Wave of ‘China Chic’ Going Global” examined how Chinese domestic brands are integrating traditional design elements with modern innovation to expand overseas. The Luggage & Bags Industry Transformation Forum on May 1 discussed market upgrades and unveiled WGSN’s 2026 Spring/Summer Accessories Trend Report, while the Sports Industry Innovation Forum on the same day spotlighted technology adoption and global brand-building strategies.

Together, these forums reinforced the Canton Fair’s role as a strategic platform for sharing industry foresight, fostering innovation, and supporting Chinese enterprises in their expansion journey into global markets.

 

Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)

SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of a Phase 3 clinical study of mazdutide , a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with overweight or obesity (GLORY-1) have been published in The New England Journal of Medicine (NEJM) with a related editorial [https://www.nejm.org/doi/full/10.1056/NEJMoa2411528]. The first authors of this paper are Professor Linong Ji from Peking University People’s Hospital and Professor Jiang Hongwei from the First Affiliated Hospital of Henan University of Science and Technology. In addition, Professor Linong Ji and Dr. Lei Qian from Innovent Biologics, served as the co-corresponding authors.

This marks the first time that a clinical study of mazdutide, the world’s first dual GCG/GLP-1 receptor agonist submitted for marketing, has been featured in a top-tier, peer-reviewed medical journal. It is also the first time a clinical trial of an innovative metabolic and endocrine therapy developed in China has been published in NEJM, a milestone that highlights China’s growing capabilities in drug development and biotechnology innovation. This publication is expected to contribute to the evolving global clinical guidelines for the treatment of overweight and obesity.

Regarding this groundbreaking new study, Professors Vanita R. Aroda of Harvard Medical School and Brigham and Women’s Hospital, Boston, and Leigh Perreault of the University of Colorado Anschutz Medical Campus jointly commented that the GLORY-1 trial reveals distinct characteristics in the Chinese population compared to Western populations. Specifically, younger individuals in China exhibit metabolic dysfunction at rates comparable to or even exceeding those in older Western populations. The dual GCG/GLP-1 receptor agonist therapy demonstrated not only significant reductions in body weight and BMI but also comprehensive improvements in obesity-associated systemic health risks. Moreover, they emphasized that obesity interventions in China must adopt differentiated strategies tailored to local population features, with a focus on liver health and lipid management. Given the earlier onset of obesity in China and its heavier societal burden, earlier intervention is critical—and yields greater long-term benefits. For emerging obesity therapies, the experts noted that pharmacological treatments are only one component of a broader strategy. They advocated for synergizing drug therapies with public health policies to build a comprehensive prevention and treatment system, addressing the global obesity epidemic more effectively.

Mazdutide is expected to launch in China this year, with anticipated approvals for weight management and glycemic control. Recognized for its superior weight loss efficacy and comprehensive metabolic benefits, mazdutide has been ranked among FIERCE Pharma’s 2025 Top 10 Most Anticipated Drugs.

In the GLORY-1 study, a total of 610 participants with obesity (BMI ≥ 28 kg/m2) or overweight (24 kg/m2 ≤ BMI < 28 kg/m2) with at least one obesity-related comorbidity were enrolled and randomized to receive mazdutide 4 mg, 6 mg, or placebo, administered subcutaneously once weekly for 48 weeks. The co-primary endpoints were the percentage change in body weight from baseline and a weight reduction of ≥5% at week 32.

At baseline, the mean weight was 87.2 kg, and the mean BMI was 31.1 kg/m 2. The study results showed that mazdutide significantly reduced body weight compared to placebo at both 4 mg and 6 mg doses.

Based on the efficacy estimand, the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. A total of 76.3% of participants in the mazdutide 4 mg group and 84.0% in the mazdutide 6 mg group had a weight reduction of ≥5% at week 32, compared with 10.9% in the placebo group; 37.0% of participants in the mazdutide 4 mg group and 50.6% in the mazdutide 6 mg group had a weight reduction of ≥15% at week 48, compared with 2.1% in the placebo group.

The primary endpoint and all key secondary endpoints of the study showed statistically significant superiority to placebo with p-values < 0.001 (main results as follows).

Efficacy Estimand1

Treatment-policy estimand2

Mazdutide

4 mg (N=203)

Mazdutide

6 mg (N=202)

Placebo

 (N = 205)

Mazdutide

4 mg (N=203)

Mazdutide

6 mg (N=202)

Placebo

 (N = 205)

Co-primary endpoint s  (Week 32)

Percent weight reduction

−10.97%

−13.38%

−0.24%

−10.09%

−12.55%

0.45 %

Achieved a weight reduction ≥5%

76.3 %

84.0 %

10.9 %

73.9 %

82.0 %

10.5 %

Some key secondary endpoints (Week 48)

Percent weight reduction

−12.05%

−14.84%

−0.47%

−11.00%

−14.01%

0.30 %

Achieved a weight reduction ≥5%

73.5 %

82.8 %

11.5 %

71.6 %

81.6 %

10.8 %

Achieved a weight reduction ≥10%

55.2 %

67.9 %

2.9 %

53.5 %

66.7 %

2.6 %

Achieved a weight reduction ≥15%

37.0 %

50.6 %

2.1 %

35.7 %

49.5 %

2.0 %

Waist circumference reduction

−9.48 cm

−10.96 cm

−1.48 cm

−9.12 cm

−10.72 cm

−1.41 cm

 

1.        Efficacy estimand aims to estimate the study treatment effect when participants adhered to the planned treatment regimen.

2.        Treatment policy estimand aims to evaluate the efficacy regardless of intercurrent events (early discontinuation of study treatment and initiation of new anti-obesity medication or bariatric surgery).

Mazdutide also significantly reduced blood pressure, blood lipids (total cholesterol, triglycerides, and low-density lipoprotein cholesterol), serum uric acid, transaminase levels, and other cardiovascular and metabolic indicators.

In addition, mazdutide significantly reduced liver fat content.

  • Among participants with baseline liver fat content ≥ 5%, the mean percent changes in liver fat content from baseline to week 48 were −63.26%, −73.18%, and +8.20% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively;
  • Among participants with baseline liver fat content ≥ 10%, the mean percent change from baseline in liver fat content to week 48 were −65.85%, −80.24%, and −5.27% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively.

Good overall safety and tolerability of mazdutide were reported.

  • The overall safety profile of the mazdutide group was consistent with findings from previous studies of mazdutide and aligned with that of other GLP-1 receptor agonists. The most frequently reported treatment-emergent adverse events included nausea, diarrhea, and vomiting, which were mostly mild or moderate in severity.
  • At Week 48, both the mean change from baseline in heart rate was 2.6 beats per minute in both the mazdutide 4 mg and 6 mg groups. There were no safety signals of increased cardiovascular risk observed throughout the study.

Professor Linong Ji, the Leading Principal Investigator of the Study, Peking University People’s Hospital, stated, “For decades, global obesity management guidelines have predominantly relied on data from Caucasian populations, resulting in limited applicability to Asian demographics. Meanwhile, China’s overweight/obese population exhibits distinct clinical characteristics and therapeutic needs compared to Western populations, necessitating evidence-based weight management strategies specifically tailored for Chinese patients. For most Chinese patients with overweight or obesity, the recommended weight loss target should be 5%-15% reduction maintained over 3-6 months. Moderate-to-severe obesity patients may require more ambitious goals. The GLORY-1 study, conducted in Chinese populations aligned with these targets, demonstrated promising outcomes: mazdutide achieved >15% weight reduction in nearly half of participants, indicating its efficacy across people living with overweight to severe obesity.

Published in The New England Journal of Medicine, the GLORY-1 study not only signifies international recognition of China’s innovative research in endocrine-metabolic disorders but also underscores the pioneering innovation of Chinese biopharmaceutical industry. Mazdutide’s successful development will accelerate domestic enterprises’ strategic presence in obesity management, enabling comprehensive, personalized solutions for China’s overweight/obese population throughout their treatment journey.”

Dr. Lei Qian from Innovent Biologics, stated, “Mazdutide is globally first dual GCG/GLP-1 receptor agonist to be approved soon. The publication of its pivotal study GLORY-1 in The New England Journal of Medicine marks a breakthrough in China’s drug development in endocrine and metabolic diseases. The study provides robust, high-quality clinical evidence for treating overweight and obesity in Chinese adults and will undoubtedly influence future clinical guidelines, diagnostic criteria, and standards of care. This academic achievement also demonstrates the exceptional clinical research capabilities of Chinese investigators and the solid innovative R&D abilities of Innovent. With mazdutide’s imminent approval in China, we look forward to offering an advanced therapeutic option to improve the health and quality of life of individuals living with overweight or obesity. As an innovative pharmaceutical company, Innovent has actively responded to and promoted the goal of ‘Healthy China 2030’ by advancing science-based weight management through strategic collaborations and cutting-edge medical achievements. “

About Obesity

China has the world’s largest population of individuals with overweight or obesity[1], a trend that is likely to rise. Obesity is associated to multiple comorbidities, and is a major contributor to reduced life expectancy and quality of life. In 2019, overweight and obesity accounted for 11.1% of deaths from chronic non-communicable diseases in China, nearly doubling from 5.7% in 1990[2].

Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited. While lifestyle interventions remains the cornerstone of treatment, many patients struggle to achieve or maintain meaningful weight reduction. This underscores the urgent need for safe, effective and sustainable pharmacological interventions.

About Mazdutide (IBI362)

Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.

Mazdutide currently has two NDAs accepted for review by NMPA, including:

  • For chronic weight management in adults with overweight or obesity;
  • For glycemia control in adults with type 2 diabetes.

Mazdutide is currently being evaluated in six Phase 3 clinical studies, including:

  • GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity.
  • GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity.
  • GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD).
  • DREAMS-1: A Phase 3 trial in treatment-naïve Chinese patients with T2D.
  • DREAMS-2: A Phase 3 trial comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on oral antidiabetic drugs.
  • DREAMS-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese patients with T2D and obesity.

Among these, GLORY-1, DREAMS-1 and DREAMS-2 studies have all met their endpoints, and other studies are currently ongoing.

In addition, several new clinical studies of mazdutide are planned, including:

  • A Phase 3 trial in adolescents with obesity.
  • A Phase 3 trial in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity.
  • New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF).

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: (1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

( 2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

[1] Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373–92.

[2] Institute for Health Metrics and Evaluation. Global Health Data Exchange. GBD results tool. http://ghdx.healthdata.org/gbd-resultstool (accessed Jan 10, 2021).

 

iQOO Neo 10 Debuts with Flagship Dual Chips, Delivering Breakthrough Performance and Industry-Leading Battery Life

DONGGUAN, China, May 26, 2025 /PRNewswire/ — iQOO officially unveils the latest addition to Neo lineup—iQOO Neo 10, featuring a powerful dual-chip setup that redefines performance in its class. With next-level performance powered by a flagship-grade Snapdragon® platform and a cutting-edge Supercomputing Chip, a class-leading combination of a large-capacity battery and FlashCharge technology, and a high-refresh-rate, eyecare display built for gaming, iQOO Neo 10 delivers a one-stop flagship-grade experience for users who demand it all.

The newly released iQOO Neo 10, powered by a dual-chip setup of Snapdragon® 8s Gen 4 Mobile Platform and Supercomputing Chip Q1, delivers an experience beyond expectations.
The newly released iQOO Neo 10, powered by a dual-chip setup of Snapdragon® 8s Gen 4 Mobile Platform and Supercomputing Chip Q1, delivers an experience beyond expectations.

Flagship-Level Dual-Chip Setup Brings Breakthrough Performance

Empowered by Qualcomm’s first all-big-core architecture processor, iQOO Neo 10 unleashes extraordinary performance to its fullest. The latest Snapdragon® 8s Gen 4 Mobile Platform features a flagship-grade CPU, delivering a performance boost of 49% and an energy efficiency improvement of 39% compared to the previous generation, with an AnTuTu Benchmark score of 2426162.(1) iQOO Neo 10 offers stronger performance, lower power consumption, faster responsiveness, and greater stability across the board. Whether users are multitasking or running heavy-duty games, the experience stays smooth, efficient, and consistent. The device also supports up to 16 GB of LPDDR5X Ultra RAM, and with Extended RAM enabled, it can keep up to 52 apps active in the background—ensuring seamless switching and effortless handling of high-frequency, multitasking scenarios.

Setting itself apart in its category, iQOO Neo 10 features a dual-chip setup, equipped with the flagship-grade Supercomputing Chip Q1, delivering an immersive, top-tier gaming experience. Through deep synergy between the Supercomputing Chip Q1 and algorithms, iQOO Neo 10 achieves exceptional image processing, supporting Game Super Resolution and industry-leading Ultra-Low-Latency Frame Interpolation—boosting frame rates to up to 144 FPS. It’s also compatible with major video platforms like YouTube and Netflix, offering ultra-clear visuals that go beyond native resolution. Along with numerous game-specific features, iQOO Neo 10 elevates the gaming experience across multiple dimensions, including priority scheduling, visual display, and complete sensory interaction.

To handle intense usage scenarios, iQOO Neo 10 features iQOO’s largest-ever vapor chamber—the same flagship-grade VC cooling system with a surface area of 7000 mm²,(2) precisely covering key heat sources. This advanced 7K Ultra VC Cooling System ensures sustained, stable performance even during extended gaming or heavy loads, keeping the device cool while helping gamers stay at their peak. Additionally, areas with localized heat sources, such as the front-facing camera, are equipped with Pyrolytic Graphite Sheet to maintain stable and smooth performance during prolonged live streaming or video recording sessions.

Industry-Leading Battery System for Ultra-Long, Stable Endurance

iQOO Neo 10 marks a breakthrough in battery capacity, advancing to an equivalent 7000 mAh for a truly long-lasting power experience. Powered by the Gen 3 Silicon BlueVolt Battery, it delivers reliable, high-performance usage—even in extreme cold conditions as low as -20℃. Thanks to cutting-edge innovations, iQOO Neo 10 breaks industry limits by achieving both high energy density and ultra-fast charging. Its 120W FlashCharge leads the industry in power efficiency, enabling the battery to charge faster—reaching 100% from 0% in just 36 minutes. It’s further enhanced by flagship-level Bypass Charging, which powers the device directly through the charger. This reduces battery heat during charging, enhances safety, and extends overall battery lifespan.

A Next-Gen Flagship Eyecare Display with Upgraded Aesthetics

iQOO Neo 10 takes display technology to new heights. Its 1.5K 144 Hz Eyecare AMOLED Display is engineered for both performance and comfort, offering a truly immersive visual experience. Backed by SGS Five-Star Sunlight Readable Display Certification, iQOO Neo 10 offers peak brightness of up to 2000 nits, ensuring crystal-clear visibility even in intense outdoor light. To further protect eye health, it also adopts 4320 Hz PWM Dimming along with Full-Range DC-Like Dimming, significantly reducing screen flicker and visual fatigue. Whether binge-watching shows, scrolling through short videos, or diving into long gaming sessions, users can enjoy a smooth, vivid, and comfortable viewing experience.

iQOO Neo 10’s flagship-level EyeCare display and lightweight design deliver an impressive visual experience and comfortable grip.
iQOO Neo 10’s flagship-level EyeCare display and lightweight design deliver an impressive visual experience and comfortable grip.

iQOO Neo 10 showcases a design philosophy that is clean, premium, youthful, and beyond expectations. With iQOO’s signature futuristic design language, it evokes a unique sci-fi exploration vibe. The device comes in a range of color options, including the sophisticated gold and the vibrant orange, combining high recognizability with bold self-expression. The lightweight body ensures a comfortable grip, with an overall thickness of 8.09 mm and a weight of just 206g, allowing for effortless use even during extended periods.

Flagship-Worthy Imaging Performance

Equipped with a flagship-level main camera and cutting-edge algorithms, iQOO Neo 10 sets a new standard in mobile photography. The 50 MP Sony IMX882 OIS Camera supports advanced full-pixel autofocus, ensuring fast and precise focus in a variety of complex shooting scenarios. Enhanced by flagship-grade NICE algorithms, it optimizes image depth and color reproduction, making every photo vivid, natural, and breathtakingly detailed. Whether capturing Nautical Blue Urban Night View or professional-grade portraits, iQOO Neo 10 delivers exceptional results with ease.

With its flagship-level main camera and advanced algorithms, iQOO Neo 10 brings every photo to life, making them vivid and natural.
With its flagship-level main camera and advanced algorithms, iQOO Neo 10 brings every photo to life, making them vivid and natural.

Designed for Reliability, Engineered for Efficiency

Built to last, iQOO Neo 10 delivers uncompromising durability and reliability. Its reinforced Durable Comprehensive Cushioning Structure, Shield Glass, and Drop-Resistant Protective Film work in tandem to significantly enhance drop resistance—certified to meet Military-Grade Certification. With an IP65 rating for dust and water resistance, it’s ready to take on everyday splashes and dust with ease, adapting effortlessly to dynamic environments. Built on Funtouch OS 15, the system delivers a 60-Month Smooth Experience with pioneering anti-aging capabilities.

Advanced AI capabilities take efficiency to the next level, empowering users to seamlessly navigate both work and life demands. From intelligent image editing to productivity tools and system interactions, iQOO Neo 10 delivers deep, multi-scenario AI integration—offering a smarter, smoother, and more efficient user experience across the board.

Availability

iQOO Neo 10 will be released in India on May 26, Malaysia on May 29, and Indonesia and Thailand on June 4. United Arab Emirates and Saudi Arabia as of mid-June.

At the same time, iQOO Z10, which is more focused on daily use scenarios and has received widespread praise since its launch in India on April 15, is now also stepping into various markets alongside iQOO Neo 10, offering a differentiated experience for users who value long-lasting performance.

About iQOO

iQOO, a sub-brand of vivo, differentiates itself in performance and Esports experience. iQOO leverages the research, quality assurance and after-sales service expertise of vivo, and follows the brand ethos of I Quest On and On to push boundaries, innovate boldly and share the excitement of exploring future technology. With products offering Esports-standard capabilities, iQOO aims to become the top choice of consumers who are passionate about performance and gaming.

For more information, please visit https://www.iqoo.com/en.

(1)The score data was obtained from iQOO laboratory tests based on AnTuTu Benchmark V10.4. The test device is the 16 GB + 512 GB edition of iQOO Neo 10. The data is for reference only. Actual scores may vary according to different phone memory editions and test environments.

(2)The VC size is based on data from the iQOO laboratory. The actual size may slightly vary due to production batches, processes variations, and measurement methods.